Arcadia Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Arcadia Biosciences, Inc. carries a market capitalization of 1.01M, placing it among publicly traded companies globally. Its enterprise value stands at -1.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.01M |
| Enterprise Value | -1.50M |
Share Statistics
Arcadia Biosciences, Inc. currently has 2.06M shares outstanding.
| Shares Outstanding | 2.06M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.47, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 0.47 |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | -0.52 |
| P/OCF Ratio | -0.52 |
Enterprise Valuation
| EV / Sales | 0.27 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Arcadia Biosciences, Inc. maintains a current ratio of 3.79, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.79 |
| Quick Ratio | 3.04 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -101.82 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 1.83 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.93 |
Stock Price Statistics
Arcadia Biosciences, Inc.'s stock has declined approximately -84.91879% over the past 52 weeks. The 50-day moving average sits at 0.85, while the 200-day moving average is 2.13.
| Beta (5Y) | N/A |
| 52-Week Price Change | -84.91879% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 2.13 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Arcadia Biosciences, Inc. generated 4.76M in revenue and converted that into -9.32M in net income, yielding earnings per share of -5.80. EBITDA reached -9.53M, while operating income came in at -9.55M.
| Revenue | 4.76M |
| Gross Profit | 1.64M |
| Operating Income | -9.55M |
| Pretax Income | -9.31M |
| Net Income | -9.32M |
| EBITDA | -9.53M |
| EBIT | -9.55M |
| Earnings Per Share (EPS) | -5.80 |
Balance Sheet
Total book value stands at -285.54M, with working capital of 3.80M providing operational flexibility.
| Cash & Cash Equivalents | 3.72M |
| Total Debt | N/A |
| Net Debt | -954,000.00 |
| Equity (Book Value) | -285.54M |
| Book Value Per Share | -177.83 |
| Working Capital | 3.80M |
Cash Flow
Arcadia Biosciences, Inc. produced -4.25M in operating cash flow over the past twelve months.
| Operating Cash Flow | -4.25M |
| Capital Expenditures | N/A |
| Free Cash Flow | -4.25M |
| FCF Per Share | -2.65 |
Margins
Arcadia Biosciences, Inc. operates with a gross margin of 34.49, reflecting its pricing power and cost economics. The operating margin of -200.78 and net profit margin of -195.94 provide insight into operational efficiency.
| Gross Margin | 34.49 |
| Operating Margin | -200.78 |
| Pretax Margin | -195.78 |
| Profit Margin | -195.94 |
| EBITDA Margin | -200.21 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -81.01 |
| FCF Yield | -191.61 |
Stock Splits
Arcadia Biosciences, Inc.'s most recent stock split took place on March 1, 2023 with a 40:1 split ratio.
| Last Split Date | 3/1/2023 |
| Split Ratio | 40:1 |
Scores
Arcadia Biosciences, Inc. posts an Altman Z-Score of -79.33, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -79.33 |